Cargando…

DRACP: a novel method for identification of anticancer peptides

BACKGROUND: Millions of people are suffering from cancers, but accurate early diagnosis and effective treatment are still tough for all doctors. Common ways against cancer include surgical operation, radiotherapy and chemotherapy. However, they are all very harmful for patients. Recently, the antica...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Tianyi, Hu, Yang, Zang, Tianyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739480/
https://www.ncbi.nlm.nih.gov/pubmed/33323099
http://dx.doi.org/10.1186/s12859-020-03812-y
_version_ 1783623339394203648
author Zhao, Tianyi
Hu, Yang
Zang, Tianyi
author_facet Zhao, Tianyi
Hu, Yang
Zang, Tianyi
author_sort Zhao, Tianyi
collection PubMed
description BACKGROUND: Millions of people are suffering from cancers, but accurate early diagnosis and effective treatment are still tough for all doctors. Common ways against cancer include surgical operation, radiotherapy and chemotherapy. However, they are all very harmful for patients. Recently, the anticancer peptides (ACPs) have been discovered to be a potential way to treat cancer. Since ACPs are natural biologics, they are safer than other methods. However, the experimental technology is an expensive way to find ACPs so we purpose a new machine learning method to identify the ACPs. RESULTS: Firstly, we extracted the feature of ACPs in two aspects: sequence and chemical characteristics of amino acids. For sequence, average 20 amino acids composition was extracted. For chemical characteristics, we classified amino acids into six groups based on the patterns of hydrophobic and hydrophilic residues. Then, deep belief network has been used to encode the features of ACPs. Finally, we purposed Random Relevance Vector Machines to identify the true ACPs. We call this method ‘DRACP’ and tested the performance of it on two independent datasets. Its AUC and AUPR are higher than 0.9 in both datasets. CONCLUSION: We developed a novel method named ‘DRACP’ and compared it with some traditional methods. The cross-validation results showed its effectiveness in identifying ACPs.
format Online
Article
Text
id pubmed-7739480
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77394802020-12-17 DRACP: a novel method for identification of anticancer peptides Zhao, Tianyi Hu, Yang Zang, Tianyi BMC Bioinformatics Research BACKGROUND: Millions of people are suffering from cancers, but accurate early diagnosis and effective treatment are still tough for all doctors. Common ways against cancer include surgical operation, radiotherapy and chemotherapy. However, they are all very harmful for patients. Recently, the anticancer peptides (ACPs) have been discovered to be a potential way to treat cancer. Since ACPs are natural biologics, they are safer than other methods. However, the experimental technology is an expensive way to find ACPs so we purpose a new machine learning method to identify the ACPs. RESULTS: Firstly, we extracted the feature of ACPs in two aspects: sequence and chemical characteristics of amino acids. For sequence, average 20 amino acids composition was extracted. For chemical characteristics, we classified amino acids into six groups based on the patterns of hydrophobic and hydrophilic residues. Then, deep belief network has been used to encode the features of ACPs. Finally, we purposed Random Relevance Vector Machines to identify the true ACPs. We call this method ‘DRACP’ and tested the performance of it on two independent datasets. Its AUC and AUPR are higher than 0.9 in both datasets. CONCLUSION: We developed a novel method named ‘DRACP’ and compared it with some traditional methods. The cross-validation results showed its effectiveness in identifying ACPs. BioMed Central 2020-12-16 /pmc/articles/PMC7739480/ /pubmed/33323099 http://dx.doi.org/10.1186/s12859-020-03812-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhao, Tianyi
Hu, Yang
Zang, Tianyi
DRACP: a novel method for identification of anticancer peptides
title DRACP: a novel method for identification of anticancer peptides
title_full DRACP: a novel method for identification of anticancer peptides
title_fullStr DRACP: a novel method for identification of anticancer peptides
title_full_unstemmed DRACP: a novel method for identification of anticancer peptides
title_short DRACP: a novel method for identification of anticancer peptides
title_sort dracp: a novel method for identification of anticancer peptides
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739480/
https://www.ncbi.nlm.nih.gov/pubmed/33323099
http://dx.doi.org/10.1186/s12859-020-03812-y
work_keys_str_mv AT zhaotianyi dracpanovelmethodforidentificationofanticancerpeptides
AT huyang dracpanovelmethodforidentificationofanticancerpeptides
AT zangtianyi dracpanovelmethodforidentificationofanticancerpeptides